Matsuura K, Ichiya Y, Ayabe Z, Kuwabara Y, Otsuka M, Das Gunasekera R
Department of Radiology, Faculty of Medicine, Kyushu University, Japan.
Radiat Med. 1987 Sep-Oct;5(5):183-5.
Gallium-67 DFO-DAS-fibrinogen scintigraphy was performed in four patients for the detection of tumor and thrombosis. No adverse reactions were noted. Scintigrams in a patient with bronchogenic carcinoma accompanied with atelectasis showed abnormal uptake not only in the cancerous region but also in the whole atelectatic region as well. In a patient with hepatoma after TAE, a slight uptake of tracer was noted in the area surrounding the tumorous region, indicating accumulation of the tracer in the microthrombi. In two patients with venous thrombosis, no abnormal uptake was seen. The long interval from the onset of thrombus formation and the commencement of anticoagulant therapy prior to scintigraphy may have caused the false-negative scans in these cases. Further evaluation is necessary with regard to the usefulness of this technique in clinical practice.
对4例患者进行了镓-67 DFO-DAS-纤维蛋白原闪烁扫描,以检测肿瘤和血栓形成。未观察到不良反应。1例伴有肺不张的支气管肺癌患者的闪烁扫描显示,不仅癌灶区域,而且整个肺不张区域均有异常摄取。1例TAE术后肝癌患者,在肿瘤区域周围可见示踪剂轻度摄取,提示示踪剂在微血栓中积聚。2例静脉血栓形成患者未见异常摄取。血栓形成至闪烁扫描前开始抗凝治疗的时间间隔较长,可能导致了这些病例的假阴性扫描结果。关于该技术在临床实践中的实用性,还需要进一步评估。